Form 4: Director Bruce Booth Executes Kymera Stock Sales

Director Bruce Booth exercised stock options and sold shares of Kymera Therapeutics under a pre-arranged 10b5-1 trading plan.

Summary

• Director Bruce Booth exercised options for 6,359 shares of Kymera Therapeutics common stock at an exercise price of $14.18 per share.
• Following the exercises, the reporting person sold a total of 9,494 shares across multiple transactions on April 14 and April 15, 2026.
• Sales were executed at weighted average prices ranging from $89.95 to $90.10 per share.
• Transactions were conducted pursuant to Rule 10b5-1 trading plans adopted in December 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, these transactions were pre-planned and represent standard liquidity events for long-term board members.

Positives

• The transactions were executed under pre-established Rule 10b5-1 trading plans, indicating a systematic approach to liquidity rather than reactive selling.
• The exercise of options at $14.18 against market prices near $90.00 demonstrates significant value realization for the director.

Negatives

• The filing reflects a reduction in direct beneficial ownership of common stock by the reporting person.

Risks

• Continued selling by insiders may be perceived by the market as a signal that the stock has reached a valuation peak.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling in the biotechnology sector is common following significant share price appreciation, particularly when executed via pre-planned 10b5-1 programs to avoid regulatory scrutiny regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.
• The volume of shares sold relative to the director's total holdings is consistent with typical portfolio rebalancing activities for biotech board members.

Related Party Transactions

• The reporting person is a member of Atlas Venture Associates X, LLC and Atlas Venture Associates Opportunity I, LLC, which hold shares in the issuer.

Stakeholder Impact

• Shareholders should note the reduction in direct ownership by a director, though the use of 10b5-1 plans mitigates concerns regarding potential negative sentiment.

Next Steps

• Continued monitoring of Form 4 filings for further insider activity.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Biotech, Stock Options, Rule 10b5-1